Allecra Therapeutics Competitors and Similar CompaniesClear all
Allecra Therapeutics's competitors and similar companies include Alnylam, Sorrento Therapeutics, ANI Pharmaceuticals and Oxurion.
 Allecra Therapeutics Allecra is a biopharmaceutical company focused on the development of novel treatments to combat multi-drug-resistant bacterial infections. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  ANI Pharmaceuticals ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A. |  Oxurion Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. | |
Founding Date | Founding Date 2013 | Founding Date 2002 | Founding Date 2006 | Founding Date 1996 | Founding Date 1991 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Hamburg, DE HQ Saint Louis, FR Lörrach, DE Detroit, US | Locations San Diego, US HQ San Diego, US | Locations Baudette, US HQ Oakville, CA Baudette, US | Locations Leuven, BE HQ Dublin 8, IE | |
Employees | Employees 7 | Employees 1,32324% increase | Employees 31019% decrease | Employees 33813% increase | Employees 785% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 35.2 b | Valuation ($) 3.3 m | Valuation ($) 1.2 b | Valuation ($) 1 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) $486.8m (FY, 2023) | Revenue (est.) €263k (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods $268.2m (FY, 2023) | Cost of goods N/A | Cost of goods N/A | Cost of goods €159k (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit $1.6b (FY, 2023) | Gross profit N/A | Gross profit N/A | Gross profit €2.1m (FY, 2023) |
Net income | Net income N/A | Net income ($440.2m) (FY, 2023) | Net income ($577.8m) (FY, 2022) | Net income $18.8m (FY, 2023) | Net income (€19m) (FY, 2023) |
Funding | |||||
Total funding raised | Total funding raised $ 44.4m | Total funding raised $ 1.5b | Total funding raised $ 42.6m | Total funding raised N/A | Total funding raised $ 3.9m |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View companyANI Pharmaceuticals
HQ
Baudette, US
Employees
338↑ 13% increase
ANI Pharmaceuticals develops, manufactures and markets top quality prescription pharmaceuticals, made in the U.S.A.
View companyOxurion
HQ
Leuven, BE
Employees
78↑ 5% increase
Oxurion (formerly known as ThromboGenics) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye.
View company